GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Chabiotech Co 085660.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

7,250

-0.55%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩1.27trn

FY2016FY2025

Net income

−₩109.88bn

FY2016FY2025

Free cash flow

−₩224.59bn

FY2016FY2025

Shareholders' equity

₩304.61bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩1.27trn₩1.05trn₩953.95bn₩844.58bn₩727.48bn₩664.72bn₩534.61bn₩488.60bn₩417.46bn₩449.26bn
Gross profit₩363.75bn₩275.26bn₩276.37bn₩204.55bn₩216.64bn₩216.37bn₩203.86bn₩167.72bn₩122.81bn₩151.61bn
Research and development₩24.59bn₩15.98bn₩14.61bn₩14.36bn₩13.05bn₩13.46bn₩12.23bn₩6.77bn₩9.46bn₩8.88bn
Operating income−₩48.44bn₩20.17bn−₩7.62bn−₩59.28bn₩7.42bn−₩5.97bn₩4.35bn₩18.23bn−₩6.70bn₩36.30bn
Net income−₩109.88bn−₩8.05bn−₩8.43bn−₩47.54bn−₩13.97bn−₩18.66bn₩46.37bn₩24.39bn−₩46.50bn₩16.88bn
Diluted earnings per share-1,181.85-132.83-149.72-844.93-248.28-355.06883.65464.75-926.98341.05

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩2.55trn₩2.19trn₩1.73trn₩1.61trn₩1.54trn₩1.31trn₩1.16trn₩947.53bn₩793.61bn₩768.93bn
Cash and short-term investments—₩339.51bn₩202.33bn₩238.32bn₩328.90bn₩343.83bn₩292.86bn₩254.65bn₩291.12bn₩320.44bn
Total liabilities₩1.74trn₩1.91trn₩1.07trn₩1.32trn₩1.08trn₩958.62bn₩785.74bn₩620.54bn₩562.87bn₩482.61bn
Debt₩159.91bn₩852.24bn₩449.64bn₩400.86bn₩333.84bn₩306.27bn₩223.70bn₩131.00bn₩107.64bn₩209.81bn
Shareholders' equity₩304.61bn₩284.69bn₩281.35bn₩291.73bn₩456.06bn₩355.09bn₩377.18bn₩326.99bn₩230.74bn₩286.32bn
Shares outstanding93m61m56m56m56m53m52m52m50m49m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−₩72.52bn−₩49.55bn₩11.51bn−₩20.63bn₩22.23bn₩47.00bn₩25.24bn₩75.38bn₩12.01bn₩11.29bn
Capital spending−₩152.07bn−₩98.51bn−₩74.38bn−₩128.87bn−₩115.46bn−₩126.23bn−₩107.77bn−₩78.14bn−₩36.91bn−₩34.13bn
Free cash flow−₩224.59bn−₩148.05bn−₩62.86bn−₩149.50bn−₩93.23bn−₩79.23bn−₩82.53bn−₩2.76bn−₩24.90bn−₩22.83bn
Dividends paid—————−₩128.8m−₩574.1m−₩574.1m−₩574.1m−₩1.99bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩316.43bn₩329.71bn₩346.54bn₩318.68bn₩298.90bn₩304.14bn₩275.98bn₩272.02bn
Gross profit₩86.83bn₩89.23bn₩103.96bn₩92.77bn₩81.33bn₩85.68bn₩69.30bn₩75.06bn
Operating income—₩11.14bn−₩7.11bn₩933.7m—−₩12.68bn−₩45.23bn—
Net income₩29.26bn₩15.62bn−₩18.80bn−₩11.80bn−₩58.46bn−₩20.80bn−₩22.19bn₩26.00bn
Diluted earnings per share314.74168.00-202.25-154.46-764.97-343.12-365.94428.84
Cash from operations−₩208.0m−₩64.01bn−₩35.06bn−₩1.24bn−₩3.03bn−₩33.20bn−₩49.55bn−₩12.81bn
Capital spending−₩39.94bn−₩54.49bn−₩53.09bn−₩39.95bn−₩40.51bn−₩18.92bn−₩98.50bn−₩74.23bn
Free cash flow−₩40.15bn−₩118.51bn−₩88.14bn−₩41.18bn−₩43.54bn−₩52.12bn−₩148.05bn−₩87.04bn
Total assets₩2.86trn₩2.79trn₩2.55trn₩2.33trn₩2.27trn₩2.20trn₩2.19trn₩2.07trn
Cash and short-term investments—————₩275.76bn₩339.51bn₩268.60bn
Debt₩306.48bn₩304.29bn₩159.91bn₩147.06bn₩161.40bn₩293.87bn₩344.84bn₩294.54bn
Shareholders' equity₩415.70bn₩514.86bn₩304.61bn₩344.53bn₩363.42bn₩290.39bn₩284.69bn₩333.18bn

Financial ratios

Data as of 27 Aug 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2018FY2017
Gross margin28.7%26.3%29.0%24.2%29.8%32.6%——
Operating margin-3.8%1.9%-0.8%-7.0%1.0%-0.9%——
Net margin-8.7%-0.8%-0.9%-5.6%-1.9%-2.8%——
Return on equity-36.1%-2.8%-3.0%-16.3%-3.1%-5.3%——
Return on assets-4.3%-0.4%-0.5%-3.0%-0.9%-1.4%——
Free cash flow yield——————36.1%12.0%
Revenue growth21.4%9.5%12.9%16.1%9.4%24.3%——
Earnings growth1264.3%-4.5%-82.3%240.4%-25.1%-140.2%——
Current ratio0.67x0.72x0.83x1.09x1.37x1.99x——
Debt to equity0.52x1.01x0.42x1.06x0.49x0.68x——
Equity ratio12.0%13.0%16.3%18.2%29.7%27.0%——
Interest coverage-0.88x0.54x-0.26x-2.84x0.51x-0.40x——
R&D as a share of sales1.9%1.5%1.5%1.7%1.8%2.0%——
Buybacks as a share of market value——————-4.6%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue14.5%13.8%12.4%
Operating income-6.5%52.0%18.9%
Net income32.2%42.6%22.1%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin27.6%27.2%28.2%29.9%
Operating margin-1.2%-2.3%-1.7%-0.6%
Net margin-5.1%-4.2%-3.8%-2.3%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-12.4-86.3-130.8-15.4-80.3-56.516.443.5-24.337.2
Price to sales1.10.71.20.91.51.61.42.22.71.4

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 27 Dec 2006.

FY2006
Paid in the year190.68
  • 1119-for-1033 split · 9 Apr 2025
  • 1-to-0.7262 reverse split · 2 Jun 2014

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.